MktsMarkets

ImmunityBio, Inc.
NASDAQ: IBRXKey statistics
IBRX News
Stories mentioning IBRX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 44,206 | 38,285 | 32,061 | 26,425 | 16,517 | 7,552 | 6,106 | 1,047 |
| Cost of Goods Sold | 238.00 | 382.00 | 177.00 | 136.00 | 58.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 43,968 | 37,903 | 31,884 | 26,289 | 16,459 | 7,552 | 6,106 | 1,047 |
| Operating Expenses | ||||||||
| Research & Development | 35,221 | 50,443 | 51,129 | |||||
| Sales General & Admin | 41,731 | 35,916 | 49,251 | |||||
| Total Operating Expenses | 76,952 | 86,359 | 100,380 | |||||
| Operating Income (Loss) | (69,791) | (64,683) | (55,630) | (71,285) | (64,429) | (69,400) | (80,253) | (99,333) |
| Interest Income | ||||||||
| Interest Expense | 14,843 | 15,256 | 15,474 | 15,313 | 26,021 | 29,322 | 29,787 | |
| Other Expense | (5,917) | (1,668) | (187.00) | (278.00) | (41.00) | 10.00 | 12.00 | (17.00) |
| Pretax Income | (632,788) | (62,093) | (67,309) | (92,305) | (129,900) | (59,179) | (85,752) | (134,584) |
| Tax Provision | 9.00 | (135.00) | (35.00) | 269.00 | (234.00) | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (632,782) | (61,944) | (67,253) | (92,555) | (129,646) | (59,162) | (85,729) | (134,564) |
| Earnings Per Share (Basic) | (0.62) | (0.07) | (0.07) | (0.10) | (0.15) | (0.08) | (0.12) | (0.20) |
| Earnings Per Share (Diluted) | (0.62) | (0.07) | (0.07) | (0.10) | (0.15) | (0.08) | (0.14) | (0.20) |
| Weighted Average Shares Outstanding (Basic) | 1,026,874 | 919,863 | 946,601 | 888,216 | 853,162 | 697,312 | 695,895 | 686,938 |
| Weighted Average Shares Outstanding (Diluted) | 1,026,874 | 919,863 | 946,601 | 888,216 | 853,162 | 700,443 | 697,961 | 686,938 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About IBRX
ImmunityBio, Inc. (NASDAQ: IBRX) is a stock listed on the Nasdaq Stock Market under the ticker symbol IBRX. It last traded at $8.29 (Oct 30, 2026, 4:00 PM ET), down 5.2% on the day. That gives ImmunityBio a market capitalisation of $8.8B.
Over the past 52 weeks IBRX has traded between $1.95 and $12.43.
Revenue for the quarter ended Mar 31, 2026 was $44.2M; a net loss of $632.8M. Revenue was up 168% from $16.5M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $44.2M | -$632.8M | -1431.4% |
| Dec 31, 2025 | $38.3M | -$61.9M | -161.8% |
| Sep 30, 2025 | $32.1M | -$67.3M | -209.8% |
| Jun 30, 2025 | $26.4M | -$92.6M | -350.3% |
From ImmunityBio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…